Related Experiment Video

Updated: Jun 28, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption

Lori J Ducharme1, Paul M Roman

  • 1Institute for Behavioral Research, University of Georgia, Athens, GA 30602-2401, USA. ducharmelj@gmail.com

Journal of Substance Abuse Treatment
|November 14, 2008
PubMed

Insights

Opioid treatment programs (OTPs) outside the Clinical Trials Network (CTN) differ from those within it. Program structure, not staff or client numbers, best predicts buprenorphine adoption.

Area of Science:

  • Addiction Medicine
  • Clinical Research Dissemination
  • Health Services Research

Background:

  • The Clinical Trials Network (CTN) aims to disseminate research findings to addiction treatment programs.
  • Assessing the capacity of external programs to adopt evidence-based practices, like buprenorphine treatment, is crucial.
  • Current data is lacking on how representative CTN opioid treatment programs (OTPs) are and barriers to practice diffusion.

Purpose of the Study:

  • To compare organizational, clinical, and client characteristics of CTN-participating OTPs versus a general sample of U.S. OTPs.
  • To identify factors influencing the adoption of buprenorphine treatment in OTPs.
  • To understand potential barriers to implementing evidence-based practices in addiction treatment.

Main Methods:

  • Comparative analysis of data from 49 CTN OTPs and 50 U.S. OTPs.
  • Examination of structural, staff, and client characteristics.
  • Assessment of buprenorphine adoption rates.

Main Results:

  • Significant differences were found between CTN and non-CTN OTPs across multiple variables.
  • OTP structural characteristics were stronger predictors of buprenorphine adoption than staff or caseload factors.
  • This suggests implementation strategies should consider program structure.

Conclusions:

  • Opioid treatment programs participating in research networks may not fully represent the broader field.
  • Programmatic structure is a key determinant for adopting new treatments like buprenorphine.
  • Findings inform strategies for disseminating evidence-based practices in addiction treatment.

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...